Literature DB >> 28223277

Ventricular arrhythmias and sudden death in patients taking ibrutinib.

Benjamin L Lampson1, Lijian Yu1, Robert J Glynn2, Jacqueline C Barrientos3, Eric D Jacobsen1, Versha Banerji4, Jeffrey A Jones5, Renata Walewska6, Kerry J Savage7, Gregory F Michaud8, Javid J Moslehi9, Jennifer R Brown1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28223277      PMCID： PMC7219062          DOI： 10.1182/blood-2016-10-742437

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  21 in total

1.  Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study.

Authors:  Asher Chanan-Khan; Paula Cramer; Fatih Demirkan; Graeme Fraser; Rodrigo Santucci Silva; Sebastian Grosicki; Aleksander Pristupa; Ann Janssens; Jiri Mayer; Nancy L Bartlett; Marie-Sarah Dilhuydy; Halyna Pylypenko; Javier Loscertales; Abraham Avigdor; Simon Rule; Diego Villa; Olga Samoilova; Panagiots Panagiotidis; Andre Goy; Anthony Mato; Miguel A Pavlovsky; Claes Karlsson; Michelle Mahler; Mariya Salman; Steven Sun; Charles Phelps; Sriram Balasubramanian; Angela Howes; Michael Hallek
Journal:  Lancet Oncol       Date:  2015-12-05       Impact factor: 41.316

2.  Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling.

Authors:  Julie R McMullen; Esther J H Boey; Jenny Y Y Ooi; John F Seymour; Michael J Keating; Constantine S Tam
Journal:  Blood       Date:  2014-12-11       Impact factor: 22.113

3.  Ibrutinib, an Approved Tyrosine Kinase Inhibitor as a Potential Cause of Recurrent Polymorphic Ventricular Tachycardia.

Authors:  János Tomcsányi; Zoltán Nényei; Zoltán Mátrai; Béla Bózsik
Journal:  JACC Clin Electrophysiol       Date:  2016-09-14

4.  The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy.

Authors:  Lee A Honigberg; Ashley M Smith; Mint Sirisawad; Erik Verner; David Loury; Betty Chang; Shyr Li; Zhengying Pan; Douglas H Thamm; Richard A Miller; Joseph J Buggy
Journal:  Proc Natl Acad Sci U S A       Date:  2010-07-06       Impact factor: 11.205

5.  Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial.

Authors:  Mohammed Z H Farooqui; Janet Valdez; Sabrina Martyr; Georg Aue; Nakhle Saba; Carsten U Niemann; Sarah E M Herman; Xin Tian; Gerald Marti; Susan Soto; Thomas E Hughes; Jade Jones; Andrew Lipsky; Stefania Pittaluga; Maryalice Stetler-Stevenson; Constance Yuan; Yuh Shan Lee; Lone B Pedersen; Christian H Geisler; Katherine R Calvo; Diane C Arthur; Irina Maric; Richard Childs; Neal S Young; Adrian Wiestner
Journal:  Lancet Oncol       Date:  2014-12-31       Impact factor: 41.316

6.  Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib.

Authors:  John C Byrd; Richard R Furman; Steven E Coutre; Jan A Burger; Kristie A Blum; Morton Coleman; William G Wierda; Jeffrey A Jones; Weiqiang Zhao; Nyla A Heerema; Amy J Johnson; Yun Shaw; Elizabeth Bilotti; Cathy Zhou; Danelle F James; Susan O'Brien
Journal:  Blood       Date:  2015-02-19       Impact factor: 22.113

7.  Real-world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: data from 95 consecutive patients treated in a compassionate use program. A study from the Swedish Chronic Lymphocytic Leukemia Group.

Authors:  Maria Winqvist; Anna Asklid; P O Andersson; Karin Karlsson; Claes Karlsson; Birgitta Lauri; Jeanette Lundin; Mattias Mattsson; Stefan Norin; Anna Sandstedt; Lotta Hansson; Anders Österborg
Journal:  Haematologica       Date:  2016-05-19       Impact factor: 9.941

8.  Racial differences in the incidence of cardiac arrest and subsequent survival. The CPR Chicago Project.

Authors:  L B Becker; B H Han; P M Meyer; F A Wright; K V Rhodes; D W Smith; J Barrett
Journal:  N Engl J Med       Date:  1993-08-26       Impact factor: 91.245

9.  Current burden of sudden cardiac death: multiple source surveillance versus retrospective death certificate-based review in a large U.S. community.

Authors:  Sumeet S Chugh; Jonathan Jui; Karen Gunson; Eric C Stecker; Benjamin T John; Barbara Thompson; Nasreen Ilias; Catherine Vickers; Vivek Dogra; Mohamud Daya; Jack Kron; Zhi-Jie Zheng; George Mensah; John McAnulty
Journal:  J Am Coll Cardiol       Date:  2004-09-15       Impact factor: 24.094

10.  Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.

Authors:  John C Byrd; Jennifer R Brown; Susan O'Brien; Jacqueline C Barrientos; Neil E Kay; Nishitha M Reddy; Steven Coutre; Constantine S Tam; Stephen P Mulligan; Ulrich Jaeger; Steve Devereux; Paul M Barr; Richard R Furman; Thomas J Kipps; Florence Cymbalista; Christopher Pocock; Patrick Thornton; Federico Caligaris-Cappio; Tadeusz Robak; Julio Delgado; Stephen J Schuster; Marco Montillo; Anna Schuh; Sven de Vos; Devinder Gill; Adrian Bloor; Claire Dearden; Carol Moreno; Jeffrey J Jones; Alvina D Chu; Maria Fardis; Jesse McGreivy; Fong Clow; Danelle F James; Peter Hillmen
Journal:  N Engl J Med       Date:  2014-05-31       Impact factor: 91.245
View more
  51 in total

Review 1.  Bruton Tyrosine Kinase Inhibitors: Present and Future.

Authors:  Jan A Burger
Journal:  Cancer J       Date:  2019 Nov/Dec       Impact factor: 3.360

Review 2.  Experience with ibrutinib for first-line use in patients with chronic lymphocytic leukemia.

Authors:  Gilad Itchaki; Jennifer R Brown
Journal:  Ther Adv Hematol       Date:  2017-11-28

3.  Descriptive analysis of dosing and outcomes for patients with ibrutinib-treated relapsed or refractory chronic lymphocytic leukemia in a Canadian centre.

Authors:  K Uminski; K Brown; O Bucher; I Hibbert; D H Dhaliwal; J B Johnston; M Geirnaert; D E Dawe; V Banerji
Journal:  Curr Oncol       Date:  2019-10-01       Impact factor: 3.677

Review 4.  Cardiovascular Complications Associated with Multiple Myeloma Therapies: Incidence, Pathophysiology, and Management.

Authors:  Vivek G Patel; Robert F Cornell
Journal:  Curr Oncol Rep       Date:  2019-03-05       Impact factor: 5.075

Review 5.  Targeting BTK in CLL: Beyond Ibrutinib.

Authors:  David A Bond; Jennifer A Woyach
Journal:  Curr Hematol Malig Rep       Date:  2019-06       Impact factor: 3.952

Review 6.  How I manage ibrutinib intolerance and complications in patients with chronic lymphocytic leukemia.

Authors:  Deborah M Stephens; John C Byrd
Journal:  Blood       Date:  2019-01-14       Impact factor: 22.113

7.  Ventricular Arrhythmias Following Ibrutinib Initiation for Lymphoid Malignancies.

Authors:  Avirup Guha; Mohamed H Derbala; Qiuhong Zhao; Tracy E Wiczer; Jennifer A Woyach; John C Byrd; Farrukh T Awan; Daniel Addison
Journal:  J Am Coll Cardiol       Date:  2018-08-07       Impact factor: 24.094

Review 8.  Beyond maximum grade: modernising the assessment and reporting of adverse events in haematological malignancies.

Authors:  Gita Thanarajasingam; Lori M Minasian; Frederic Baron; Franco Cavalli; R Angelo De Claro; Amylou C Dueck; Tarec C El-Galaly; Neil Everest; Jan Geissler; Christian Gisselbrecht; John Gribben; Mary Horowitz; S Percy Ivy; Caron A Jacobson; Armand Keating; Paul G Kluetz; Aviva Krauss; Yok Lam Kwong; Richard F Little; Francois-Xavier Mahon; Matthew J Matasar; María-Victoria Mateos; Kristen McCullough; Robert S Miller; Mohamad Mohty; Philippe Moreau; Lindsay M Morton; Sumimasa Nagai; Simon Rule; Jeff Sloan; Pieter Sonneveld; Carrie A Thompson; Kyriaki Tzogani; Flora E van Leeuwen; Galina Velikova; Diego Villa; John R Wingard; Sophie Wintrich; John F Seymour; Thomas M Habermann
Journal:  Lancet Haematol       Date:  2018-06-18       Impact factor: 18.959

9.  Updates from the American Society of Hematology 2019 annual meeting: practice-changing studies in treatment-naïve chronic lymphocytic leukemia.

Authors:  V Banerji; P Anglin; A Christofides; S Doucette; P Laneuville
Journal:  Curr Oncol       Date:  2020-05-01       Impact factor: 3.677

Review 10.  The cancer patient and cardiology.

Authors:  José Luis Zamorano; Christer Gottfridsson; Riccardo Asteggiano; Dan Atar; Lina Badimon; Jeroen J Bax; Daniela Cardinale; Antonella Cardone; Elizabeth A M Feijen; Péter Ferdinandy; Teresa López-Fernández; Chris P Gale; John H Maduro; Javid Moslehi; Torbjørn Omland; Juan Carlos Plana Gomez; Jessica Scott; Thomas M Suter; Giorgio Minotti
Journal:  Eur J Heart Fail       Date:  2020-10-02       Impact factor: 15.534
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.